Towards Healthcare Research & Consulting

Iliac Stents Market Next-Gen Vascular Interventions

Iliac Stents Market (By Product Type: Balloon-Expandable Stents, Bare Metal Balloon-Expandable, Covered Balloon-Expandable, Self-Expanding Stents, Bare Metal Self-Expanding, Covered Self-Expanding; By Material: Nitinol Stents, Stainless Steel Stents, Cobalt Chromium Stents, Polymer-based / Hybrid Stents; By Indication: Peripheral Artery Disease (PAD), Iliac Artery Occlusion, Restenosis Cases, Others; By End User: Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics; By Region: North America, Asia Pacific, Europe, Latin America, Middle East and Africa) Global Analysis, Size, Trends, Leading Companies, Regional Outlook and Forecast 2026 to 2035

Last Updated : 10 April 2026 Category: Medical Devices Insight Code: 6818 Format: PDF / PPT / Excel
Revenue, 2025
USD 1.15 Billion
Forecast, 2035
USD 2.22 Billion
CAGR, 2026-2035
6.8%
Report Coverage
Global

The global iliac stents market size was estimated at USD 1.15 billion in 2025 and is predicted to increase from USD 1.23 billion in 2026 to approximately USD 2.22 billion by 2035, expanding at a CAGR of 6.8% from 2026 to 2035. The iliac stents market is growing because of rising demand for stents to manage diseases such as those affecting the heart and blood vessels of ageing and middle-aged people.

Iliac Stents Market Size is USD 1.23 Billion in 2026.

Key Takeaways

  • Iliac stents industry poised to reach USD 1.23 billion by 2026.
  • Forecasted to grow to USD 2.22 billion by 2035.
  • Expected to maintain a CAGR of 6.8% from 2026 to 2035.
  • North America dominated the iliac stents market with a share of 38% in 2025.
  • Asia Pacific held 22% share of the market, expected to grow at the fastest rate of 8.2% of CAGR during the forecast period.
  • By product type, the self-expanding stents segment held 54% market share in 2025.
  • By product type, the balloon-expandable stents segment held the second-largest market share of 46% in 2025, and is expected to grow at the fastest CAGR of 7.4% during the forecast period.
  • By material, the nitinol stents segment held the largest market share of 58% in 2025 and is expected to grow at the fastest CAGR of 7.2% during the forecast period.
  • By indication, the peripheral artery disease (PAD) segment held the largest market share of 52% in 2025.
  • By indication, the restenosis cases segment held a significant market share of 16% in 2025, and is expected to grow at the fastest CAGR of 7.3% during the forecast period.
  • By end user, the hospitals segment held the largest iliac stents market share of 68% in 2025.
  • By end user, the ambulatory surgical centers (ASCs) segment held a notable market share of 20% in 2025, and is expected to grow at the fastest CAGR of 7.6% during the forecast period.

Market Overview: What are Iliac Stents?

The iliac stents market is growing, as an iliac stent is a small wire mesh tube that is used to hold open an iliac artery that has been narrowed by atherosclerotic disease.  In an iliac stenting technology, a thin guide wire is inserted into a small incision in the upper thigh. This technology is generally visualized using X-rays and a special dye that reveals the arteries. It is a minimally invasive technology to place a small metal mesh tube in the affected vein to open it actively and restore normal blood flow. Stenting opens up the blocked vein, letting blood flow freely and lowering symptoms like pain and swelling. Iliac vein stenting is a safe and efficient treatment choice for a person with iliac vein compression syndrome.

How is AI governing the Iliac Stents Market?

AI-based algorithms in iliac stents can accurately identify vital anatomical features, forecast complications, and optimize stent placement by analyzing data from imaging techniques such as intravascular ultrasound and optical coherence tomography. Fully leverage AI to improve the effectiveness and safety of interventional procedures. AI's abilities enable precise identification of anatomical details, complication prediction, and optimal stent positioning, improving procedural results.

Future Outlook & Trends in the Iliac Stents Market

  • Self-Expanding Covered Stents: A self-expanding covered stent is a larger-sized stent used with a small sheath. Due to their advantages, self-expandable stents are a substitute option in areas where large-sized balloon expandable stents are not available, and have been applied to patients with congenital heart disease in these areas
  • Next-Generation Materials: The next-generation balloon-expandable stent-graft has established notable 9-month safety and effectiveness in treating iliac occlusive disease in patients, reflecting common healthcare practice.
  • Drug-Eluting Stents (DES): Drug-eluting stents (DES) are vascular prostheses applied by interventional cardiologists to restore and preserve patent coronary arteries affected by atherosclerosis.

Quick Facts Table

Table Scope
Market Size in 2026 USD 1.23 Billion
Projected Market Size in 2035 USD 2.22 Billion
CAGR (2026 - 2035) 6.8%
Leading Region North America by 38%
Historical Data 2020 - 2023
Base Year 2025
Forecast Period 2026 - 2035
Measurable Values USD Millions/Units/Volume
Market Segmentation By Product Type, By Material, By Indication, By End User, By Region
Top Key Players Medtronic, Abbott Laboratories, Boston Scientific Corporation, Becton Dickinson, W. L. Gore & Associates, Inc.

Segmentation Analysis

Iliac Stents Market Segmentation

By Product Type Insights

Segment Share 2025 (%)
Balloon-Expandable Stents 46%
Self-Expanding Stents 54%

Self-Expanding Stents Segment Led the Iliac Stents Market in 2025       

The self-expanding stents segment contributed the largest market share of 54% in 2025, as their design enables a high degree of elasticity, relative simplicity of placement, and smaller-diameter delivery technology for large-diameter stents. A self-expandable stent allows a larger-sized stent to be used with a small sheath. They are familiar with the natural curving of blood vessels, lowering the challenges of vessel wall injury.

The balloon-expandable stents segment held the second largest share of 46%, expected to grow at the fastest CAGR of 7.4% of the market, as balloon-expandable coronary stenting has transformed the field of interventional cardiology into a potential, negligibly invasive modality for managing coronary artery disease.  It is less shocking to the patient and should carry a lower risk of dissection or vessel rupture.

By Material Insights

Segment Share 2025 (%)
Nitinol Stents 58%
Stainless Steel Stents 18%
Cobalt Chromium Stents 16%
Polymer-based / Hybrid Stents 8%

Nitinol Stents Segment Led the Iliac Stents Market in 2025

The nitinol stents segment contributed the largest market share of 58%, and it is the fastest growing in the forecast period with a 7.2% CAGR, as the stent avoids negative remodelling and provides distinct benefits over bare-stenting long SFA lesions. It reduces fracture and mechanical failure challenges. Nitinol is biocompatible; it is not toxic or harmful to living tissue. These characteristics make it a standard material for medical implants.

The stainless-steel stents segment held a significant share of 18% the market in 2025. Stainless steel is a common material because it combines processability, durability, corrosion resistance, and biocompatibility. These stents play a significant role in restoring blood flow, stabilizing vessels, and maintaining long-term vascular health.

The cobalt chromium stents segment held a significant share of the iliac stents market of 16% in 2025. Cobalt-chromium stents have condensed the restenosis rate. Cobalt–chromium stents are evolving as this material is stronger than 316 stainless steel, therefore enabling the construction of stents with thinner struts without compromising radial strength.

The polymer-based/hybrid stents segment held a significant share of 8% the market in 2025, as polymer stents offer advanced design, quality healing, and outstanding safety. They are made from polymers or metallic alloys and are designed to prevent restenosis and encourage normal vessel function throughout their absorption period.

By Indication Insights

Segment Share 2025 (%)
Peripheral Artery Disease (PAD) 52%
Iliac Artery Occlusion 24%
Restenosis Cases 16%
Others 8%

The Conventional Dialysis Technology Segment held the Largest Share in the Market in 2025

The peripheral artery disease (PAD) segment contributed the largest iliac stents market share of 52% in 2025, as stenting is a significant procedure that can significantly improve blood flow and enhance the quality of life for patients with peripheral artery disease. Stenting evades the challenges of early elastic recoil, residual stenosis, and flow-limiting dissection after balloon angioplasty.

The iliac artery occlusion segment held a notable share of the market of 24% in 2025, as stent placement for iliac artery occlusion lowers major procedural complications compared with PTA.  It's improved blood flow to the legs via the artery being treated.

The restenosis cases segment held a notable share of 16% the iliac stents market in 2025, expected to grow at the fastest CAGR of 7.3% of the market, as repeat stenting with enviroximes-eluting stents presented a statistical advantage over other methods in the primary results, binary restenosis rates, and target lesion revascularization. Drug-eluting stents have transformed the practice of interventional cardiology. They are safe and efficient in dramatically enhancing patient results.

By End User Insights

Segment Share 2025 (%)
Hospitals 68%
Ambulatory Surgical Centers (ASCs) 20%
Specialty Clinics 12%

The Hospitals Segment held the Largest Share in the Market in 2025

The hospitals segment contributed the largest iliac stents market share of 68% in 2025, as iliac venous stenting provides long-term relief from CPP even with residual OVR and post-stent pregnancy. With 73% of women having full pain resolution. Stenting supports alleviating painful symptoms caused by iliac vein compression, like heaviness, swelling, achiness, discoloration, and restless legs.

The ambulatory surgical centers (ASCs) segment held the second largest share of 20%, expected to grow at the fastest CAGR of 7.6% of the market, as stenting for iliac vein outflow obstruction is related to excellent long-term stent patency and symptom resolution. Endovascular stenting enables same-day discharge, removing the requirement for long hospital stays related to open surgical reconstruction.

The specialty clinics segment held a notable share of 12% the market in 2025, as this is a minimally invasive, outpatient alternative to traditional open surgery. Patients frequently report a noteworthy advancement in QoL, involving better sleep, lower pain, and augmented mobility.

Regional Insights

Iliac Stents Market Shares for North America, Europe, Asia Pacific, Latin America and Middle East and Africa, 2025 (%).

Why North America Dominated the Market in 2025?

Iliac Stents Market Size is USD 0.37 Billion in 2026.

In 2025, North America dominated the iliac stents market with a share of 38% in 2025, because of the advancement in R-PCI with a focus on developments in robotic expertise, procedural difficulty, tele-stenting, and training processes. Significant industry players like Medtronic, Abbott, and W. L. Gore & Associates have strong production and research presences in the region.

For Instance,

  • In October 2025, Elixir Medical, an inventor of disruptive technologies to manage cardiovascular disease, announced novel landmark clinical outputs for its DynamX bioadaptor, a coronary implant intended to restore a blood vessel’s natural movement and function, also called hemodynamic modulation.

U.S. Market Trends

The U.S. has a population of more than 330 million people and is supported by one of the most challenging healthcare systems in the world. This region has well-developed industrial countries. The region has a massive incidence of PAD, diabetes, and obesity, increasing demand for advanced iliac stents.

Asia Pacific: Increasing Cases of CVD

Asia Pacific held 22% share of the market. expected to experience the fastest growth with 8.2% CAGR during the forecast period, the rising CVD epidemics in this region are the consequence of challenging effects from interrelated changes in socioeconomics and living environments, demography, lifestyles, the prevalence of CVD risk factors, and the increasing demand for iliac stents. The quickly aging population in the Asia-Pacific region has the potential to create a severe health crisis, which contributes to the growth of the market.

India Market Trends

Peripheral arterial disease (PAD) is one of the underdiagnosed and undertreated vascular diseases despite its noteworthy burden in India. In India, the etiological aspects, diagnostic strategies, treatment modalities, and other preventive measures may diverge in different regions. Government hospitals often opt for domestic stents because of their affordability.

Supply Chain Analysis

R&D:

  • The research and development (R&D) process for iliac stents includes pre-clinical material and intended engineering, computational modelling and testing, pre-clinical evaluation, healthcare evaluation, regulatory trials, and post-market surveillance
  • Key Players: Boston Scientific Corporation and Becton Dickinson 

Manufacturing Processes:

  • The manufacturing of iliac stents, healthcare tools used to keep iliac arteries or veins open, includes a multi-stage process divided into the primary fabrication, secondary cutting and shaping, and significant post-processing.
  • Key Players: Medtronic and Abbott Laboratories 

Patient Services:

  • Patient services include a comprehensive, minimally invasive strategy covering pre-procedure assessment, the intervention, and post-procedural care.
  • Key Players: Venovo and Wallstents

Latest Updates of Key Players in the Iliac Stents Market

Iliac Stents Market Companies are Medtronic, Abbott Laboratories, Boston Scientific Corporation, Becton Dickinson

Company Headquarters Latest Update
Medtronic Ireland Medtronic has identified that a small subset of Abre stent lots contain stents with potential for a smaller-than-expected stent diameter due to a variation in Nitinol material properties. 
Abbott Laboratories United States In September 2025, Abbott announced that Health Canada had authorized the Esprit BTK Everolimus Eluting Resorbable Scaffold System, a first-of-its-kind treatment innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK).
Boston Scientific Corporation United States In March 2025, Boston Scientific Corporation announced that the U.S. Food and Drug Administration (FDA) had approved its Express LD Iliac Premounted Stent System for use in iliac arteries.
Becton Dickinson United States In November 2025, BD announced full enrollment of the iliac artery patient cohort in its essential AGILITY investigational device exemption (IDE) research, which is assessing the Revello vascular covered stent for the treatment of peripheral artery disease (PAD).
W. L. Gore & Associates, Inc. United States In January 2026, W. L. Gore & Associates’ medical business (Gore) announced the FDA approval of the GORE VIABAHN FORTEGRA Venous Stent, previously known as the GORE VIAFORT Vascular Stent.

SWOT Analysis

Strengths

  • Balloon dilation and stenting are safe and efficient treatments for chronic benign obstruction of the iliac vein.
  • Stenting helps alleviate painful symptoms caused by iliac vein compression, like swelling, achiness, heaviness, restless legs, and discoloration.

Weakness

  • Major challenges after iliofemoral and inferior vena cava stenting are rare, and most are managed effectively without significant long-term consequences for the patient.

Opportunities

  • Recent advancements in covered stent grafts were primarily developed to prevent acute vessel occlusion as a result of elastic recoil and the inhibition of vascular smooth muscle cell proliferation inside the lumen of the stent graft.
  • Intravascular lithotripsy (IVL) transformed the management of CAD, providing a safe and operative means of plaque alteration. Using IVL in CAD management has proven efficient in safely modifying solidified plaques, enabling optimal stent deployment and enhancing clinical results.

Threat

  • Limb-threatening and life-threatening challenges related to iliac artery stent placement.

Recent Developments in the Iliac Stents Market

  • In March 2026, BD, a foremost worldwide medical technology organization, announced it had obtained CE Marking for the Revello Vascular Covered Stent, a next-generation endovascular stent for the treatment of atherosclerotic lesions in the common and external iliac arteries.
  • In January 2025, Bentley announced the market launch of its BeFlow iliac covered stent system at the Leipzig Interventional Course.  BeFlow is intended for the treatment of iliac occlusive and stenotic diseases.

Segments Covered in the Report

By Product Type

  • Balloon-Expandable Stents
  • Bare Metal Balloon-Expandable
  • Covered Balloon-Expandable
  • Self-Expanding Stents
  • Bare Metal Self-Expanding
  • Covered Self-Expanding

By Material

  • Nitinol Stents
  • Stainless Steel Stents
  • Cobalt Chromium Stents
  • Polymer-based / Hybrid Stents

By Indication

  • Peripheral Artery Disease (PAD)
  • Iliac Artery Occlusion
  • Restenosis Cases
  • Others

By End User

  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Specialty Clinics

By Region

  • North America
    • U.S.
    • Canada 
    • Mexico 
    • Rest of North America
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Europe 
    • Western Europe 
      • Germany 
      • Italy
      • France
      • Netherlands
      • Spain
      • Portugal 
      • Belgium
      • Ireland
      • UK 
      • Iceland 
      • Switzerland
      • Poland
      • Rest of Western Europe
    • Eastern Europe 
      • Austria
      • Russia & Belarus 
      • Türkiye
      • Albania 
      • Rest of Eastern Europe 
  • Asia Pacific
    • China 
    • Taiwan
    • India 
    • Japan 
    • Australia and New Zealand
    • ASEAN Countries (Singapore, Malaysia)
    • South Korea 
    • Rest of APAC 
  • MEA 
    • GCC Countries
      • Saudi Arabia 
      • United Arab Emirates (UAE)
      • Qatar 
      • Kuwait 
      • Oman 
      • Bahrain 
    • South Africa
    • Egypt 
    • Rest of MEA

FAQ's

Finding : The iliac stents market in 2026 is valued at USD 1.23 billion and is projected to climb to USD 2.22 billion by 2035, with a CAGR of 6.8% over the forecast period.

Finding : North America was dominant in the market by 38% because of its advanced healthcare infrastructure and high prevalence of PAD.

Finding : Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB,CDC.

Tags

Meet the Team

Rohan Patil

Rohan Patil

Principal Consultant

Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

Learn more about Rohan Patil
Aditi Shivarkar

Aditi Shivarkar

Reviewed By

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar

Related Reports

Iliac Stents Market
Updated Date: 10 April 2026   |   Report Code: 6818